A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
Full description
This is an open-label, multicenter, global Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031 in patients with selected relapsed or refractory (R/R) malignancies. The study will be conducted as separate Phase 2, single arm substudies for each of the indications below:
- Extranodal NK/T-cell lymphoma (ENKTL)
- Peripheral T-cell lymphomas (PTCL)
- Diffuse large B-cell lymphoma (DLBCL) with PD-L1 gene translocation, copy gain, amplification, polysomy detectable by a fluorescence in situ hybridization (FISH) assay or Epstein-Barr virus positivity (EBV+) as assessed by EBV-encoded small RNA (EBER) testing
- Biliary tract cancers (BTC) (intrahepatic cholangiocarcinoma), extrahepatic cholangiocarcinoma or gallbladder cancer)
All participants will receive the study intervention, STI-3031.
Sex
Ages
Volunteers
Inclusion criteria
-
Documented histologically confirmed diagnoses of Extranodal NK/T-cell lymphoma, Peripheral T-cell lymphoma, Diffuse Large B-cell lymphoma (with a PD-L1 gene abnormality or Epstein-Barr virus positivity, or biliary tract cancer.
-
Prior treatment:
- Extranodal NK/T-cell lymphoma: Must have received at least 1 previous line of systemic therapy including an asparaginase-based regimen.
- Peripheral T-cell lymphoma: must have received at least 1 previous line of systemic multi-agent chemotherapy. Participants with anaplastic large cell lymphoma (ALCL) must have received brentuximab vedotin
- Diffuse Large B-cell lymphoma: Must have received at least 2 previous lines of systemic therapy including an anti-CD20 antibody
- Biliary Tract Cancer: Must have received at least 1 previous line of systemic therapy including gemcitabine with or without platinum
-
Documented disease progression during or after the last therapy
-
If not previously treated with transplant, Investigator considers the participant ineligible for transplant
-
Measurable disease
-
Adult age (as defined by respective country) at time of signing informed consent form (ICF)
-
Must be able to understand the nature of the study and provide a signed and dated, written ICF prior to any study-specific procedures, sample collections and analyses
-
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
-
Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment and radiopharmaceuticals are permitted if more than 8 weeks have elapsed since the end of treatment
-
At least 14 days or 5 half-lives must have elapsed since the last chemotherapy, immunotherapy, biological or investigational therapy, and have recovered from toxicities associated with such treatment to < Grade 2
-
Adequate hematologic, renal and hepatic function
-
Females of childbearing potential (FCBP) must agree to use a reliable form of contraceptive during the study treatment period and for at least 90 days following the last dose of study intervention
-
Male participants must agree to use barrier contraception (i.e., condoms) for the duration of the study and for at least 90 days after the last dose of study intervention
-
Predicted life expectancy of at least 16 weeks
Exclusion criteria
-
Current participation in another therapeutic clinical trial
-
Prior treatment with an anti-PD-L1 or anti-PD-1 antibody
-
Patients with symptomatic central nervous system (CNS) metastases unless considered adequately treated and controlled for at least 2 weeks
-
Prior hematopoietic stem cell transplantation
-
History of other previous cancer that would interfere with the determination of safety or efficacy
-
Any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and Type 1 diabetes mellitus
-
Apparent active or latent tuberculosis (TB) infection
-
Seropositive for or have active infection with hepatitis C virus (HCV), unless HCV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy
-
Seropositive for or have active viral infection with hepatitis B virus (HBV), unless HBV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy
-
Seropositive for or active viral infection with HIV, unless the following are met:
- CD4+ T-cell (CD4+) counts ≥ 350 cells/uL; and
- Participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to screening and have HIV viral load < 400 copies/mL; and
- Participant has not had acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 12 months prior to screening
-
Active infection (viral, bacterial, or fungal) requiring intravenous (IV) systemic therapy within 14 days
-
Evidence of bleeding diathesis or coagulopathy.
-
Significant proteinuria
-
Conditions requiring chronic steroid use (> 10 mg/day of prednisone or equivalent).
-
Recent history of attenuated viral vaccination within 30 days prior to the first dose of study intervention
-
Herbal preparations/medications are not allowed throughout the treatment period unless first discussed with and approved by the Medical Monitor
-
History of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients.
-
Known current drug or alcohol abuse
-
Major surgical procedures ≤ 28 days prior to the first dose of study intervention, or minor surgical procedures ≤7 days prior to the first dose of study intervention
-
Pregnant or lactating
-
Any of the following cardiac diseases currently or within the last 6 months:
- QT interval corrected using Fridericia's formula >450 milliseconds in men and > 470 milliseconds in women (up to 480 milliseconds may be allowed after discussion between the Investigator and the Medical Monitor).
- Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
- Unstable angina pectoris
- Congestive heart failure (New York Heart Association ≥ Grade 2)
- Acute myocardial infarction
- Clinically significant conduction abnormality not controlled with pacemaker or medication
- Significant ventricular or supraventricular arrhythmias (Participants with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible.)
-
Underlying medical conditions that, in the opinion of the investigator and/or medical monitor, will render the administration of study drug hazardous or obscure the interpretation of safety or efficacy results
Trial design
Primary purpose
Allocation
Interventional model
Masking
0 participants in 4 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal